Vonoprazan,Gastric Acid,Gastro
Recognizing the clinical benefits of vonoprazan over proton pump inhibitors. Find out how vonoprazan is superior to proton pump inhibitors in gastric acid management.
Potassium-competitive acid blockers (P-CABs) were first developed in the 1980s and have been worked upon for gastric acid suppression worldwide since then.1
Among P-CABs, vonoprazan is the first-in-class Food and Drug Administration-approved drug for Helicobacter pylori infection in combination with antibiotics.2 It has also become a first-choice drug for gastroesophageal reflux disease (GERD) treatment.3
Interestingly, vonoprazan has been proven efficacious in alleviating a vast array of gastric acid complications. For example, a randomized comparative study evaluated vonoprazan and lansoprazole for patients with erosive oesophagitis experiencing heartburn at least once a week.4 Vonoprazan demonstrated faster relief from heartburn compared to lansoprazole (p<0.05).4 Around 2.5 times more patients experienced complete relief from heartburn on day 1 of therapy with vonoprazan compared to lansoprazole.4 Additionally, complete nocturnal heartburn relief was also reported in significantly more patients with vonoprazan than lansoprazole (p<0.01).4
Furthermore, a prospective observational study assessed the effectiveness of vonoprazan in preventing gastric and duodenal ulcer recurrence in patients receiving non-steroidal anti-inflammatory drugs (NSAIDs).5 The overall incidence of gastric or duodenal ulcer recurrence was 1.04% with vonoprazan.5
Let’s hear to what Prof. Hidekazu Suzuki has to say about the clinical effectiveness of Vonoprazan for gastric acid complications.
Conclusion
Vonoprazan has become the first-choice drug for GERD treatment and Helicobacter pylori eradication.2,3 The drug also exhibits significant effectiveness in relieving heartburn in patients with erosive esophagitis and prevents gastric and duodenal ulcer recurrence in patients on NSAIDs.4,5
References
- Oshima T, Miwa H. Potent potassium-competitive acid blockers: A new era for the treatment of acid-related diseases. J Neurogastroenterol Motil. 2018;24(3):334–344.
- Veererathinakumar NK, Ananthy V, Codi RS, et al. Potassium-competitive acid blocker: A newer target in the treatment of acid peptic disorder. SBV J. Basic Clin. Appl. Health Sci. 2023;6(2):33–38.
- Shinozaki S, Osawa H, Hayashi Y, et al. Long-term vonoprazan therapy is effective for controlling symptomatic proton pump inhibitor-resistant gastroesophageal reflux disease. Biomed Rep. 2021;14(3):32.
- Oshima T, Arai E, Taki M, et al. Randomised clinical trial: Vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis. Aliment Pharmacol Ther. 2019;49(2):140–146.
- Kawai T, Suzuki C, Honda Y, et al. Long-term safety and effectiveness of vonoprazan for prevention of gastric and duodenal ulcer recurrence in patients on nonsteroidal anti-inflammatory drugs in Japan: A 12-month post-marketing surveillance study. Expert Opin Drug Saf. 2023;22(5):425–431.
For the use of a registered medical practitioner, hospital or laboratory only.
LMRC Code: GGI-CO-A1-AQS-300041558-APPEMC-G24-1179 DOI of 15/07/24 and DOE of 15/08/24
Vono 20-Always on Duty
Vono, containing Vonoprazan molecule, is a Potassium Competitive Acid Blocker which helps in treatment of Refractory GERD, Erosive Esophagitis, H.Pylori, Gastric & Duodenal Ulcers
